title: Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
authors.forename: A
authors.initials: A
authors.lastname: Wahba
authors.forename: A
authors.initials: A
authors.lastname: Vonk
authors.forename: B
authors.initials: B
authors.lastname: Bidstrup
mesh_terms: D000933:Antifibrinolytic Agents / Q000008:administration & dosage*; D007611:Aprotinin / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000401:mortality / Q000517:prevention & control; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D003226:Congresses as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control; D019106:Postoperative Hemorrhage / Q000401:mortality / Q000517:prevention & control; D015996:Survival Rate; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D007611:Aprotinin